NeoDynamics will release its Interim Report for January-September 2023 on 27 November 2023.
The date for publication of the Interim Report January-September 2023 has been changed from 24 November 2023 to 27 November 2023.
The delay is related to discussions regarding the capitalisation of the company, which are expected to be resolved shortly.
The company will host a conference call for investors on Tuesday 28 November 2023 at 11.00am.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail email@example.com
Aaron Wong, CFO NeoDynamics AB, phone +46790 101 714 or e-mail firstname.lastname@example.org
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing the diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institute in Sweden. NeoDynamics’ shares are listed on Nasdaq First North Growth Market Stockholm: NEOD.ST. The company’s Certified Adviser is Redeye AB.
NeoNavia® is the first vacuum-assisted device utilizing pulse technology for high yield, low risk, targeted biopsies in the breast and axillary lymph nodes. The innovative platform provides 3 needle options designed for accurate lesion targeting and greater tissue sampling with minimal trauma to surrounding tissue.
About Karolinska Institute
The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.